TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

TELA Bio, Inc.NASDAQ: TELA

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow growth accelerates

Q2 FY2026 financing cash flow of $15K (cash outflow) rose 400.0% year over year, ahead of the -40.4% change in trailing-twelve-month financing cash flow. Sequentially, it fell 95.0% from the prior quarter. Over 3 fiscal years it compounded at -14.3% a year.

Context

  • Financing cash flow amounted to 32.1% of revenue in FY2025, down 30.1 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +400.0% holds above the trailing-twelve-month pace of -40.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$15K-95.0% QoQ
Last fiscal yearDec 2025
$25.75M-40.2% YoY
LTMJun 2026
$25.56M-40.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+400.0%——
1 year-40.2%——
3-year CAGR-14.3%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
25.75M USD
Year-over-year change
-40.2%
4-year CAGR
+157.6%

Financing Cash Flow vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 financing cash flow of $25.56M is the 5th largest of the 9 companies compared; the peer median is $23.36M.
  • Its year-over-year change of -40.4% is the 8th highest of 9, against a peer median of +60.7%.
  • Financing cash flow amounts to 32.0% of revenue for TELA, versus a peer median of 337.3%.
TELA Competitors Peer median
Financing Cash Flow for TELA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EQEquillium, Inc.LTM Mar 2026$65.68M +25657.6%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026$57.81M +3300.9%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$47.24M +93.8%-8.9%14179.4%
CUECue Biopharma, Inc.LTM Mar 2026$27.6M +300.6%-21.2%84.3%
TELATELA Bio, Inc.LTM Jun 2026$25.56M -40.4%-14.3%32.0%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$19.12M +27.6%-10.3%833.6%
MDAISpectral AI, Inc.LTM Mar 2026$9.73M -18.4%—58.3%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$8.35M -18.6%+35.8%590.3%
SRTSSensus Healthcare, Inc.LTM Mar 2026$5K -98.2%-49.9%0.0%
Peer median (excluding TELA) $23.36M+60.7%-10.3%337.3%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Depreciation & Amortization535K1.19M808K1.01M1.01M
Deferred Income Tax14K00(144K)230K
Stock-Based Compensation3.66M3.99M5.03M4.36M3.8M
Change in Working Capital(3.47M)(5.76M)(1.67M)(4.87M)1.5M
Accounts Receivables(1.55M)(2.42M)(3.06M)(762K)(110K)
Inventory(5.19M)(6.07M)(2.72M)(2.97M)(503K)
Accounts Payables1.6M(884K)11K482K141K
Other Working Capital1.69M3.62M4.1M(1.62M)1.97M
Other Non-Cash Items2.1M4.14M1.64M(4.12M)4.08M
Operating Cash Flow(30.43M)(40.75M)(40.86M)(41.6M)(28.22M)
Capital Expenditures(627K)(1.87M)(611K)(989K)(448K)
Acquisitions (Net)00001.29M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(1M)12K5.44M0
Investing Cash Flow(627K)(1.87M)(599K)4.45M846K
Debt Repayment010M0014.03M
Common Stock Issued585K34.4M46.34M42.92M11.82M
Common Stock Repurchased0000105K
Dividends Paid00000
Other Financing Activities0(3.55M)(74K)138K(205K)
Financing Cash Flow585K40.85M46.27M43.06M25.75M
Effect of Forex Changes11K(144K)164K28K(217K)
Net Change in Cash(30.46M)(1.91M)4.98M5.94M(1.84M)
Free Cash Flow(31.06M)(42.62M)(41.47M)(42.58M)(28.67M)

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.